Kymera to report Phase 1 trial results of KT-621 on June 2

WATERTOWN, Mass. - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on the development of oral small molecule degrader medicines, with a current market capitalization of $1.94 billion, will announce the findings from its Phase 1 clinical trial of KT-621 on June 2, 2025. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 8.49, indicating robust liquidity to support its development programs. The trial involves single and multiple-ascending doses of the drug in healthy volunteers. The company plans to host a video webcast at 8:00 a.m. ET on the same day to discuss the results.

KT-621 is a novel oral medication targeting STAT6, a transcription factor integral to IL-4/IL-13 signaling, which is a central driver of Th2 inflammation. This drug represents the first STAT6-directed therapy to be clinically evaluated and is designed to offer the ease of an oral medicine with the potential effectiveness of injectable biologics. Preclinical studies have shown KT-621 to be safe and well-tolerated, exhibiting activity comparable to dupilumab in various in vitro and in vivo models.

The potential impact of KT-621 could be significant, as it aims to transform treatment paradigms for over 130 million patients globally suffering from Th2-mediated diseases. Wall Street appears optimistic about the company’s prospects, with InvestingPro reporting that 8 analysts have recently revised their earnings expectations upward, with price targets ranging from $38 to $97. Investors should note that while the stock shows high volatility with a beta of 2.19, the company maintains more cash than debt on its balance sheet. These conditions include atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and several others. Currently, KT-621 is also undergoing a Phase 1b trial in AD patients, with results expected in the fourth quarter of 2025.

Kymera Therapeutics is also preparing to initiate two parallel Phase 2b clinical trials for KT-621 targeting moderate to severe AD and asthma, slated to start in the fourth quarter of 2025 and the first quarter of 2026, respectively. These trials are designed to expedite the development of KT-621 and assist in determining dosages for future Phase 3 registration studies across multiple Th2-related indications in dermatology, gastroenterology, and respiratory fields.

Kymera is a leader in targeted protein degradation (TPD), with a mission to create treatments for diseases that are challenging to address with existing therapies. Founded in 2016, the company has been recognized for its innovative workplace in Boston. While the company reported an EBITDA of -$271.67 million in the last twelve months, InvestingPro analysis reveals additional insights about the company’s financial health and market position. For deeper analysis and access to over 10 additional ProTips, including detailed valuation metrics and growth indicators, consider exploring the comprehensive Pro Research Report available on InvestingPro.

The upcoming webcast and the clinical trial results are anticipated to provide further insights into KT-621’s therapeutic potential and its development progress. The information is based on a press release statement from Kymera Therapeutics, Inc.

In other recent news, Kymera Therapeutics has been in the spotlight due to several significant developments. The company has reported promising preclinical data for its oral STAT6 degrader, KT-621, which has shown comparable or superior activity to dupilumab in a chronic asthma model. This potential treatment for asthma and other related diseases is expected to offer a convenient once-daily oral option. Kymera has completed a Phase 1 trial for KT-621, with full data anticipated in June 2025, and plans for further trials in atopic dermatitis and asthma are underway.

Analyst firms have also weighed in on Kymera’s prospects. Stifel has reinstated coverage with a Buy rating and a price target of $55, highlighting the company’s innovative degrader platform. BTIG adjusted its price target for Kymera to $55 from $60, maintaining a Buy rating, while Truist Securities continues to support the stock with a Buy rating and varying price targets, citing the company’s strategic focus and pipeline expansion. Notably, Kymera has introduced a new oral IRF5 degrader, KT-579, and discontinued its TYK2 degrader program to concentrate on more promising areas.

These strategic decisions are expected to extend Kymera’s cash runway into the first half of 2028, allowing the company to focus on advancing its STAT6 program and IRF5-targeting therapies. Investors are encouraged by the anticipated data releases and the potential for Kymera’s treatments to address significant unmet needs in immunological diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.